MINNEAPOLIS, Sept. 26, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding ...

Uroplasty, Inc., a medical device company with headquarters in Minnetonka, Minn., has received a patent for its Urgent PC Neuromodulation System and stimulation methods for treating overactive bladder ...

This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and ...

) today announced two new research and development initiatives to expand its commitment to using the Company's neuromodulation technology to treat voiding dysfunctions. "We will begin development of ...

Oct. 28, 2005 — The U.S. Food and Drug Administration (FDA) has approved a total-body dual-energy x-ray absorptiometry system for use as an aid in the detection and diagnosis of osteoporosis, and for ...

Urine Cytology Adds Little to Hematuria Investigation In most responders, overactive bladder symptom improvement sustained to three years. Percutaneous tibial nerve stimulation with the Urgent PC ...

Uroplasty UPI, a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced significant new coverage decisions by ...

United Healthcare, the nation's largest health insurer, has agreed to cover a unique electrical stimulation system that treats symptoms of an overactive bladder. The system, called the Urgent PC ...

Uroplasty Inc. said Monday two additional private insurance plans will now cover its nerve stimulation device system to treat symptoms of overactive bladder. The Plymouth-based medical device company ...

Neuspera Medical’s percutaneous sacral neuromodulation (pSNM) has hit the “gold standard”, with 84.2% of patients suffering incontinence benefitting from a 50% reduction in urgent leaks and a more ...